Shaers of Novo Nordisk A/S (NYSE:NVO) have been recommended as a long term growth pick according to Beta Research. With the firm’s stock price currently trading around $48.83, the firm has proven a solid track record of growth over the past few years. Investors might consider the stock as a long term growth candidate as the firm has yielded 20.10% earnings per share growth over the past 5 years and 11.00% revenue growth over that same time frame.
Let’s take a look at how the stock has been performing recently. Over the past twelve months, Novo Nordisk A/S (NYSE:NVO)’s stock was 36.17%. Over the last week of the month, it was -0.47%, 13.93% over the last quarter, and 35.56% for the past six months.
Over the past 50 days, Novo Nordisk A/S’s stock is -1.35% off of the high and 18.84% removed from the low. Their 52-Week High and Low are as follows: -1.35% (High), 58.08%, (Low).
Despite the past success, investors want to know where the stock is headed from here. Analysts covering the shares have a consensus short-term price target of $50.20 on the equity. Analysts have a consensus recommendation of 3.00 based on a 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.